In vitro anticancer activity (IC₅₀) of aloe emodin and its derivatives (1, 2, 5a–5k, and 6a–6e) against cancer cell lines. Concentration that promotes 50% of cell growth inhibition after 48 h of treatment. IC₅₀ was determined by the MTT assay. The independent experiment was run at least three times.

Compound	MDA-MB-231a	MCF-7a	HEPG2b	B16F10c	HEK-293d
1	12.24 ± 0.15 μM	4.14 ± 0.37 μM	6.13 ± 0.25 μM	3.12 ± 1.25 μM	1.00 ± 0.78 μM
2	4.99 ± 0.26 μM	2.68 ± 0.74 μM	3.15 ± 0.43 μM	2.90 ± 1.27 μM	4.49 ± 1.42 μM
5a	21.70 ± 0.9 μM	3.18 ± 0.15 μM	12.35 ± 0.53 μM	2.22 ± 1.49 μM	4.56 ± 1.23 μM
5b	0.90 ± 0.40 μM	1.04 ± 1.35 μM	1.00 ± 2.16 μM	1.85 ± 1.43 μM	1.03 ± 1.69 μM
5c	7.56 ± 0.37 μM	1.13 ± 2.46 μM	1.35 ± 2.54 μM	1.57 ± 0.25 μM	2.47 ± 1.28 μM
5d	3.96 ± 1.15 μM	3.58 ± 1.42 μM	6.23 ± 0.87 μM	3.35 ± 0.27 μM	9.76 ± 0.57 μM
5e	4.46 ± 1.85 μM	0.87 ± 1.02 μM	3.35 ± 1.66 μM	1.15 ± 0.43 μM	9.32 ± 0.80 μM
5f	6.20 ± 1.96 μM	3.96 ± 1.45 μM	2.16 ± 0.55 μM	3.90 ± 0.49 μM	1.09 ± 0.60 μM
5g	0.99 ± 0.32 μM	6.35 ± 1.56 μM	1.15 ± 0.69 μM	3.46 ± 1.26 μM	1.12 ± 1.57 μM
5h	2.16 ± 0.65 μM	8.98 ± 0.97 μM	1.26 ± 0.95 μM	8.15 ± 2.85 μM	9.07 ± 1.48 μM
5i	1.85 ± 0.99 μM	7.26 ± 0.75 μM	2.6 ± 0.24 μM	5.40 ± 0.36 μM	1.93 ± 0.32 μM
5j	1.15 ± 0.16 μM	4.62 ± 0.95 μM	1.34 ± 1.55 μM	3.46 ± 0.79 μM	1.97 ± 2.12 μM
5k	4.70 ± 0.36 μM	3.86 ± 1.96 μM	5.68 ± 1.24 μM	2.15 ± 0.37 μM	10.13 ± 1.35 μM
6a	6.78 ± 1.36 μM	9.96 ± 1.85 μM	3.41 ± 1.75 μM	5.61 ± 0.25 μM	8.86 ± 0.18 μM
6b	1.32 ± 0.13 μM	0.99 ± 0.36 μM	5.62 ± 0.18 μM	9.57 ± 0.99 μM	30.11 ± 0.05 μM
6c	1.49 ± 1.16 μM	4.66 ± 0.49 μM	3.46 ± 0.32 μM	3.34 ± 1.34 μM	5.01 ± 1.88 μM
6d	3.68 ± 0.63 μM	1.16 ± 0.13 μM	2.29 ± 0.46 μM	6.09 ± 0.27 μM	6.84 ± 0.65 μM
6e	1.66 ± 0.25 μM	2.68 ± 0.25 μM	3.99 ± 0.70 μM	6.06 ± 0.14 μM	21.22 ± 0.05 μM
Doxorubicin	2.56 ± 0.27 μM	2.02 ± 0.24 μM	2.35 ± 2.16 μM	3.28 ± 1.65 μM	1.65 ± 1.85 μM

^aHuman breast cancer cells.

^bHuman liver cancer cells.

^cHuman skin melanoma cancer cells.

^dNormal cells.